12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ZP2929: Phase I started

Zealand began a double-blind, U.S. Phase I trial to evaluate single ascending-doses of daily ZP2929 in healthy volunteers. The trial start triggers a €5 million ($6.4 million) milestone payment to Zealand...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >